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2012.06.0Abstract Background and purpose: The role of Epstein-Barr virus (EBV) in breast carcinogenesis
is still controversial. Unraveling this relationship is potentially important for better understanding
of breast cancer etiology, early detection and possibly prevention of breast cancer. The aim of the
current study is to unravel the association between EBV and primary invasive breast cancer (PIBC)
in two different Arab populations (Egyptian and Iraqi women).
Patients and Methods: The study was done on parafﬁn-embedded tissues of 40 Egyptian and 50
Iraqi patients with PIBC in addition to 20 normal breast tissues as controls for each group. Both
controls and neoplastic tissues were assessed for the expression of EBV genes and proteins
(EBNA-1, LMP-1, and EBER) as well as CD21 marker by immunohistochemistry (IHC), in situ
hybridization (ISH) and PCR techniques.
Results: Our gold standard for EBV reactivity in breast cancer cases was positivity of both EBNA1
by PCR and EBER by in situ hybridization. EBV was detected in 18/40 (45%) and 14/50 (28%) of
Egyptian and Iraqi women; respectively where p= 0.073, compared to 0/20 (0%) of their control
groups (p< 0.05). Regarding the association between EBV positivity and tumor grade, there was
not any statistical signiﬁcant difference between EBV presence and tumor grade in both populations413521; fax: +20 223644720.
.-R.N. Zekri).
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124 A.-R.N. Zekri et al.where p= 0.860 and p= 0.976 and the calculated rank biserial correlation coefﬁcient was 0.114
and 0.269 for Egyptian and Iraqi women respectively.
Conclusion: Our ﬁndings show that EBV might act as a promoter for the development of PIBC and
it might contribute to increased tumor aggressiveness in Egyptian and Iraqi patients.
ª 2012 National Cancer Institute, Cairo University. Production and hosting by Elsevier B.V.
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Breast cancer is the most frequently diagnosed malignancy of
women in many populations [1]. In Egypt, breast cancer
ranked ﬁrst among all tumors presented to the National Can-
cer Institute (NCI), Cairo, where it represents 17.5% of all
diagnosed cancer cases [2]. Researches into breast cancer etiol-
ogy have focused primarily on reproductive and other factors
affecting circulating sex hormones and on genetic susceptibil-
ity. However, as identiﬁed risk factors are thought to explain
the incidence in about half of all breast cancer cases only,
researchers are motivated to consider other routes for disease
pathogenesis [3–6]. Viruses have been implicated in the devel-
opment of various cancers, but they have not been much con-
sidered for breast cancer. Identiﬁcation of the mouse
mammary tumor virus (MMTV) supports a viral etiology for
breast tumors in animals, though similar germ line viral se-
quences found in humans are not believed to play any direct
role in carcinogenesis [7]. Detection of Epstein-Barr virus
(EBV) in the neoplastic tissues of breast cancer cases has been
reported by some authors [8–13]. The relationship between
breast cancer and EBV could be of potential importance not
only for better understanding of breast cancer etiology, but
also for early detection, prevention of breast cancer and treat-
ment. A possible association of EBV with breast cancer was
proposed as a consequence of the high incidence of male breast
cancers, which was reported in Mediterranean countries, an
area endemic for EBV; also, the occurrence of some EBV-
associated lymphomas in the breast, and the morphological
similarities between medullary carcinoma of the breast and
nasopharyngeal carcinoma (NPC) [14]. EBV sequences were
found in breast tissues and milk, and transfection of p31 frag-
ment of EBV DNA has been shown to immortalize epithelial
cells including mammary epithelial cells [1]. Furthermore, it
has been reported that breast cancer cells are heterogeneous
in terms of EBV genome content and distribution and this
raises the possibility that even though EBV might have no eti-
ological role, it can still contribute to tumor development [14].
Most of the studies performed to date to assess the associ-
ation between EBV infection and breast carcinoma have been
done in Western countries, however, consistent results have to
be demonstrated from studies conducted all over the world in
order to establish a causal relationship. So far, few studies
have been reported from Asian countries [13,15,16] and from
Egypt [17–19]. In the current study, a combined approach
has been applied to overcome the limitation of commonly used
methods for EBV detection in breast cancer, which have lym-
phocytic inﬁltrates. Each patient was screened for EBNA1
presence by PCR followed by EBER by in situ hybridization
(ISH) to localize the EBV and then LMP1gene was ampliﬁed
by PCR. Also, CD21 detection by IHC was done in order to
localize and target EBV receptors. Therefore, our study was
conducted to determine the possible relation between EBVinfection and primary invasive breast carcinoma (PIBC) cases
in two different Arab populations; Egyptian and Iraqi pa-
tients; also, to assess the geographic variability as seen in other
malignancies associated with EBV.
Patients and methods
Patients and tissue specimens
This study was done on 40 Egyptian and 50 Iraqi patients with
PIBC, in addition to 20 normal breast tissue samples from
each country as a control group. All patients were newly diag-
nosed and none of them had a previous history of breast car-
cinoma or any other malignancy. Parafﬁn blocks of breast
tissues were obtained from the Pathology Departments of
the National Cancer Institute, Cairo University, Egypt, from
January 2010 to September 2010 and at the same period, from
Baghdad Medical College, Baghdad University, Iraq. For each
tumor block, ﬁve (4l thick sections) were cut onto positive-
charged slides for routine histopathological examination,
immunohistochemistry (IHC) and in situ hybridization
(ISH). Another ﬁve (10l thick sections) were cut into a sterile
Eppendorf tube for subsequent DNA extraction. A written
consent was obtained from all patients prior to enrollment in
the study, and the ethical committees of the NCI and Baghdad
University approved the protocol, which was in accordance
with the ethical guidelines of the 2008 Declaration of Helsinki.
EBER in situ hybridization (ISH)
In situ hybridization for the detection of EBV-speciﬁc RNAs
(EBER) was performed using kits from Dako, Glostrup,
Denmark. Samples were analyzed by microscopy for EBER-
stained nuclei. Sections from EBV-positive nasopharyngeal
carcinoma were used as positive controls.
Immunohistochemistry
The standard streptavidirin-biotin-peroxidase detection tech-
nique was performed as previously described [20] using the
mouse monoclonal antibody for CD21 (CD21 A-3, Santa Cruz
biotechnology, California, USA) against EBV membrane
receptor and LMP-1 (Santa Cruz biotechnology, California,
USA). The antigen retrieval method was performed by micro-
wave pretreatment in 0.01 M citrate buffer (pH 6.0). Manufac-
turer’s protocols were followed for all procedures. The primary
antibody was applied and incubated overnight at 4 C in a
humidiﬁed chamber and after 3 washes in PBS, the secondary
antibody and the avidin–biotin complex (ABC) were applied
to slides. Diaminobenzidine (DAB) was used as a chromogen
and sections were counterstained using Mayer’s hematoxylin.
To evaluate the speciﬁcity of the antibodies, known positive
and negative tissues were used as controls. Assessment of
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pattern. Cases were considered positive with >10% stained
cells.
DNA extraction
High molecular weight DNA was extracted from the parafﬁn
sections according to standard protocols. Brieﬂy, samples were
de-waxed twice with 1 mL xylene for 10 min, washed twice
with 100% ethanol, dried and re-suspended in 500 ll PK buf-
fer [50 mmol/L KCl, 10 mmol/LTris–HCl (pH8.3), 2.5 mmol/
L MgCl2, 100 lg/mL gelatin, 0.45% Tween20] and 100 lg/
mL proteinase K. Samples were digested overnight at 55 C,
extracted with phenol: chloroform: isoamyl, ethanol precipi-
tated. Nucleic acid was dissolved in 100 lL TE storage buffer.
Polymerase chain reaction (PCR)
Tumor and normal DNA were used for PCR, which was done
to detect EBNA-1 and LMP-1 expression as previously de-
scribed by Hashimoto et al. [21]. PCR products were electro-
phoresed in 2% ethidium bromide-stained agarose gel and
visualized with UV light transilluminator (Fig. 1).
Statistical analysis
Statistical analyses were carried out using a program of statis-
tical package for social sciences (SPSS) version 18 (PASW
IBM Corp., USA, 2010). Numerical data (age) were presented
as mean ± standard deviation (SD) or median and range.
Qualitative variables, such as EBV viral markers’ presence
and clinicopathological features for Egyptian and Iraqi pa-
tients, were expressed by frequencies and percentage. Compar-
ison between age groups for Egyptian and Iraqi cases was done
using the t-test as appropriate. Differences between Egyptian
and Iraqi EBV-Positive Breast Carcinomas with regard to clin-
icopathological features were examined using either Chi-
square test (v2) or Fisher’s exact test when appropriate. Rank
biserial correlation coefﬁcient was calculated for studying the
strength of association between ordinal variable (tumor grade)Figure 1 Data on gene ampliﬁcation. Ethidium bromide-stained 2% a
breast cancer case. Lane 2 showed negative ampliﬁcation of LMP1 gene
4 showed molecular weight marker.and nominal variable (EBV presence). p-value <0.05 was con-
sidered signiﬁcant.
Results
EBV positivity in breast cancer cases
Our gold standard for EBV positivity in breast cancer cases
was the detection of EBNA1 antigen by PCR and EBER1
by in situ-hybridization assay. We performed EBER in situ
hybridization on the PCR positive cases to localize the positive
signal. PCR-Egyptian positive cases were 23/40(57.5%). Out
of those 23 patients, 18(45%) cases were positive for EBER
(ISH). From those 18 patients, 12(30%) cases were positive
for LMP1 (PCR), as illustrated in Fig. 1. Detection of
LMP1 antigen by PCR method can distinguish the latent
EBV from non-latent infection that was conﬁrmed by the pres-
ence of EBV by immunohistochemistry technique in the breast
cancer tissues, as shown in Fig. 2. On the other hand, PCR-
Iraqi positive cases were 16/50(32%). Out of those 16 patients,
14(28%) cases were positive for EBER (ISH), and 11(22%)
cases were positive for LMP1 (PCR). In other words, 11 Iraqi
patients had EBV latent infection. Also, CD21 detection by
IHC was done in order to localize and target EBV receptors,
where it was found in 22/40(55%) and 16/50(32%) of Egyptian
and Iraqi patients, respectively. Table 1 shows the frequency of
different EBV markers by each technique (LMP1 and EBNA1
by PCR or EBER by ISH, or CD21 by IHC) in the Egyptian
and Iraqi groups in addition to their controls. The highest fre-
quency was reported using EBNA-1 PCR assay, where it was
positive in 57.5% Egyptian patients. However, the lowest prev-
alence was reported using LMP1 by PCR assay in 22% of
Iraqi patients.
Our results demonstrated that EBV positivity in PIBC tis-
sues was (45%) and (28%) in Egyptian and Iraqi patients
respectively (Table 2), while it was absent in the control group
0/20(0%) of both populations. There was a highly statistically
signiﬁcant difference between the prevalence of EBV in tumor
and normal tissue samples in both populations (p= 0.0001
and p= 0.005 for Egyptian and Iraqi cases, respectively).garose gel (Lane 1) showed positive ampliﬁcation of LMP1 gene in
in breast cancer case. Lane 3 showed Negative-PCR control; Lane
Figure 2 Legend: (A) A case of invasive duct carcinoma showing positive cytoplasmic immunostaining for LMP-1, (B&C) A case of
invasive duct carcinoma showing positive membranous immunostaining for CD21, (D) A case of invasive duct carcinoma showing
positive nuclear in situ hybridization with EBER-1.
Table 1 Frequency of EBER1, EBNA1, LMP1, and CD21 viral markers in Egyptian and Iraqi EBV-positive breast carcinomas,
detected by; in situ hybridization, immunohistochemistry, or PCR technique.
Parameter No. EBER1 (ISH)% EBNA1 (PCR)% LMP1 (PCR)% CD21 (IHC)%
Egyptian patients 40 18 (45%) 23 (57.5%) 12 (30%) 22 (55%)
Controls 20 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Iraqi patients 50 14 (28%) 16 (32%) 11 (22%) 16 (32%)
Controls 20 0 (0%) 0 (0%) 0 (0%) 1 (5%)
EBER: EBV-encoded small nonpolyadenylated RNA, EBNA-1: EBV nuclear antigen-1, LMP-1: latent membrane antigen-1, PCR: polymerase
chain reaction.
Table 2 Clinicopathological features of Egyptian and Iraqi EBV-Positive Breast Carcinomas, detected by both EBNA1 (PCR) and
EBER1(ISH) techniques.
Features Egyptian patients (+)ve cases% p-value Iraqi patients (+)ve cases% p-value
Age (years)
<30–<50 11/23 (47.8) 0.46 12/41 (29.2) 0.51
50–680 7/17 (41.1) 2/9 (22.2)
Histology
Ductal 14/32 (43.8) 0.53 11/42 (26.2) 0.40
Lobular 4/8 (50) 3/8 (37.5)
Tumor grade
I ½ (50) 0.93 2/9 (22.2) 0.79
II 13/28 (46.4) 10/32 (31.2)
III 4/10 (40) 2/9 (22.2)
Total 18/40 (45) 14/50 (28)
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Table 3 Some previously published studies which evaluated EBV infection in breast cancer specimens by different assays.
Authors, year Country Patients No. Tumor type Assay EBV positivity
Luqmani and
Shousha (1995)
[8]
England 28 Invasive
carcinoma, various
Nested PCR for BamH1W 54%
ISH for EBER 0%
IHC for LMP1 Focal positive
Labrecque et al.
(1995) [9]
England 91 Invasive
carcinoma, various
PCR for BamHI-W 21%
PCR for EBERs 17/34 (50%)
19 ISH for BamH1W DNA 12/19 PCR+
ISH for EBER1 RNA 6/19 (32%)
Chu et al. (1998)
[10]
Taiwan 60 Invasive ductal
carcinoma
IHC for EBNA2 0%
Some with medullary features IHC for LMP1 0%
ISH for EBER1 0%
Glaser et al.
(1998) [11]
US 107 Invasive carcinoma, various ISH for EBER1 0%
Bonnet et al.
(1999) [12]
France 100 Invasive ductal, lobular PCR for EBER2,
BZLF1, LMP2
51%
other carcinomas
ISH for EBER1 0/3 PCR+
Southern blot for
BamH1W 7/7 (100%)
IHC for EBNA1 9/9 (100%)PCR+
Brink et al.
(2000) [35]
Holland 24 Carcinoma PCR for BamH1W 21%
PCR for LMP1 2/5 (40%) PCR+
rtPCR for BamH1A RNA 0/5 PCR+
rtPCR for EBNA1 RNA 0/5 PCR+
IHC for EBNA1 1/5 (20%) PCR+
ISH for EBER1/2 0/5 PCR+
McCall et al.
(2001) [45]
US 115 Intraductal, invasive Microdissection
and PCR for EBNA1 2/115 (2%)
ISH for EBER 1/2 (50%) PCR+
IHC for LMP1 1/2 PCR+
Dadmanesh
et al. (2001) [43]
Italy 4 Lymphoepithelioma-like
Carcinoma ISH for EBER1 0%
Kijima et al.
(2001) [44]
Japan 61 Carcinoma ISH for EBER1 0%
Fina et al.
(2001) [36]
North Africa, Europe 509 Invasive ductal carcinoma PCR for EBER 32%
ISH for EBER1 10/20 (50%) PCR+
Microdissection and
RT PCR for EBER1 2/2 (100%)
Chu et al. (2001)
[46]
US 48 Invasive carcinoma IHC for EBNA1 25%
IHC for LMP1 0%
IHC for BZLF1 0%
ISH for EBER1 10%
PCR for EBNA-4 (EBNA-3b) 10%
PCR for LMP1 10%
Southern blot for
EBV clonality 0/6 PCR+
Grinstein et al.
(2002) [37]
US 33 Inﬁltrating ductal and
lobular carcinoma
IHC for EBNA1 42%
PCR for EBER 14/14 (100%)
Herrmann and
Niedobitek
(2003) [47]
Germany 59 Invasive ductal, lobular,
medullary
and undiﬀerentiated
carcinoma
PCR for BamH1 W DNA 7%
ISH for EBER1 RNA 0%
ISH for BamH1W 0%
IHC for EBNA1 0%
Murray et al.
(2003) [48]
UK 153 Inﬁltrating ductal, carcinoma in situ,
medullary, and mucinous RT PCR for Pol 19/92 (21%)
Microdissection 0/19 PCR+
ISH for EBER 0/19 PCR+
IHC for EBNA1 31%
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Table 3 Some previously published studies which evaluated EBV infection in breast cancer specimens by different assays.
Authors, year Country Patients No. Tumor type Assay EBV positivity
Preciado (2003)
[38]
North and South America 102 Carcinoma IHC for EBNA1 38/102 (37%)
PCR for BamH1W and EBER 24/69 (35%)
Kalkan et al.
(2005) [49]
Turkey 57 invasive ductular, lobular, and PCR for EBVDNA 13/57(23%)
Other miscellaneous carcinomas
Perkins et al.
(2006) [39]
USA 24 invasive breast carcinoma real time PCR for
EBVDNA 11/24(46%)
Mohamed et al.
(2007) [18]
Egypt 34 invasive breast carcinoma IHC for LMP-1 6/34(17.6%)
PCR for EBVDNA 12/34(35.3%)
Fawzy et al.
(2008) [19]
Egypt 40 invasive breast carcinoma IHC for EBNA-1 10/40(25%)
PCR for EBVDNA 8/40(20%)
Joshi et al.
(2009) [13]
India 58 invasive ductular, lobular, and IHC for EBNA-1 28/51(54.9%)
Other malignant carcinomas
Lorenzetti et al.
(2010) [40]
Argentine 71 invasive carcinoma IHC for LMP2A, 16/71(22.5%)
IHC for EBNA1 22/71(31%)
IHC for LMP1 0/71(0%)
ISH for EBER 0/71(0%)
PCR for EBV DNA 22/71(31%)
EBNA1 23/40(57.5%) 40 Egyptian cases invasive breast carcinoma PCR for
ISH for EBER1 18/40(45%)
PCR for LMP1 12/40(30%)
IHC for CD21 22/40(55%)
Current study
(2011)
Egypt
50 Iraqi cases invasive breast carcinoma PCR for EBNA1 16/50(32%)
ISH for EBER1 14/50(28%)
PCR for LMP1 11/50(22%)
IHC for CD21 16/50(32%)
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(45%) than Iraqi patients (28%), but this difference was statis-
tically insigniﬁcant (p= 0.073).
Clinicopathological ﬁndings
Egyptian patients’ age ranged from 27 to 76 years with a mean
age of 48.48 ± 11.16 years, while Iraqi patients’ age ranged
from 27 to 63 years with a mean age of 42.18 ± 9.06 years.
Invasive duct carcinoma (IDC) constituted 80% (32/40) of
the Egyptian cases and 84% (42/50) of the Iraqi cases, whereas
invasive lobular carcinoma (ILC) constituted 20% (8/40) of
the Egyptian cases and 16% (8/50) of the Iraqi cases. In the
Egyptian group, 2 cases (5%) were grade I, 28 (70%) were
grade II, and 10 (25%) were grade III while, 9 out of the 50
Iraqi cases (18%) were grade I, 32 (64%) were grade II, and
9 (18%) were grade III (Table 2).
Relationship of EBV reactivity with pathological features
Regarding the association between EBV positivity and tumor
grade, there was not any statistical signiﬁcant difference be-
tween EBV presence and tumor grade in both populations
where p= 0.860 and p= 0.976, and the calculated rank bise-
rial correlation coefﬁcient was 0.114 and 0.269 for Egyptian
and Iraqi women respectively.Discussion
EBV was classiﬁed as a group-1 carcinogen by IARC Working
Group [22]. However, the associated cancers vary markedly in
viral prevalence, from nearly 100% of nasopharyngeal carci-
noma (NPCs) to about 10% of gastric carcinomas [23–25],
and also differ in the patterns of viral genes expressed, suggest-
ing that EBV may affect cell growth in more than one way [25].
Thus, EBV infection represents an important but not a sufﬁcient
step in carcinogenesis, and epidemiological risk factors have
been shown to play an additional critical role in this process.
Indirect support for an association of EBV with breast can-
cer comes from observations that: (a) EBV is present in breast
tissue, where it is detected in breast milk in some women [26];
(b) transfection of EBV DNA stimulates growth of human
breast milk cells [27]; (c) some EBV-associated lymphomas oc-
cur in the breast [28,29]; (d) breast cancer has epidemiological
similarities to young-adult Hodgkin’s lymphoma, although
evidence for breast cancer implicates timing of primary EBV
infection rather than viral oncogenesis [30]; (e) EBV has been
identiﬁed in benign breast tumors in immunosuppressed wo-
men [31]; (f) in vitro, breast epithelial cells can be infected by
direct contact with EBV-bearing lymphoblastoid cell lines
[32]; and (g) Regarding serological evidence, measurement lev-
els of anti-EBNA-1 Immunoglobulin (IgG) antibodies in
stored sera of Breast Cancer Indian Women was previously
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Immunosorbent Assay (ELISA) kit, in which patients with be-
nign breast diseases were used as a comparison group for both
immunohistochemical and serological analysis.
In the current study, multiple analytical assays have been
used for evaluation of different EBV gene products under
study. First assay was In situ Hybridization for EBER detec-
tion where it enables us for differentiating EBV in tumor cells
from EBV in surrounding lymphocytes. Second and third as-
says were PCR for ampliﬁcation of EBNA-1 and LMP-1
detection where PCR is potentially a highly sensitive and spe-
ciﬁc method but it cannot differentiate EBV in malignant
breast epithelial cells from EBV in surrounding lymphocytes.
The fourth assay was Immunohistochemistry for CD21 detec-
tion in order to localize and target EBV receptors.
Our results have shown that EBV positivity in PIBC tissues
was (45%) and (28%) in Egyptian and Iraqi patients respec-
tively. This observation may be explained by the fact that
EBV DNA presence in breast cancer patients can differ be-
tween groups with different demographic distributions and
population characteristics, as stated by Wiencke [33]. In other
words, distribution of HLAs may differ in Egyptian population
than in Iraqi population. However, because of the numbers of
samples tested, these observations should be conﬁrmed in pop-
ulation-based studies involving larger numbers of samples.
In addition, EBV detection was absent in the control group
of both populations (p< 0.05), where the normal breast tissues
were obtained from different normal subjects. Although most
of the previous studies have used normal breast tissues distant
to tumor, we preferred to assess EBV in normal breast tissues
obtained from reduction mammoplasty specimens for two rea-
sons. First, several previous studies on different solid tumor
types provided evidence that what is called adjacent normal tis-
sues is only morphologically normal since many molecular
changes have been detected in these areas. Second, in most
breast cancer cases the adjacent normal tissues contain many
inﬂammatory cells and lymphocytes which are the normal res-
ervoir for EBV and this could affect the ﬁnal results [34–35].
This ﬁnding is in close to the previous study done by Joshi
et al. [13] where they found that about 55% of breast cancer
Indian women cases showed EBNA-1 expression in tumor cells
by IHC, while all the controls with benign breast disease were
negative. Also, two Egyptian authors Mohamed et al. [18] and
Fawzy et al. [19] have reported EBV infection in 35.3% and
25% of invasive breast carcinoma respectively; however, those
three studies had certain limitations, where they looked for
expression of only one viral protein. They should have investi-
gated multiple EBV proteins present in different phases of viral
latency seen in other EBV associated tumors. Also, our ﬁnd-
ings are close to numerous studies done by Horiuchi et al.
[36], Luqmani and Shousha [8], Labrecque et al. [9], Bonnet
et al. [12], Brink et al. [37], Fina et al. [38], Grinstein et al.
[39], Xue et al. [27], Preciado, [40], Perkins et al. [41], and
Lorenzetti et al. [42], where EBV infection has been found
most consistently and in a prevalence of about 10–50% using
PCR method, and histochemical methods have produced evi-
dence of viral DNA or proteins within the breast cancer cells
that suggests a pathogenic role of EBV. Although EBV infec-
tion has been found by several authors, it has been completely
undetected by others such as Gaffey et al. [43], Lespagnard
et al. [44], Glaser et al. [11], Dadmanesh et al. [45], and Kijima
et al. [46], as illustrated in Table 3. The inconsistency andapparent variability of these ﬁndings should not itself exclude
a role of EBV in breast carcinogenesis because it is inﬂuenced
to some extent by three issues: First, the marked variation in
EBV prevalence even among studies using the similar tech-
niques as the studies done by Bonnet et al. [12], Brink et al.
[37], and Deshpande et al. [51]; Second, the possibility of
false-positive or -negative analytical test results due to lympho-
cyte-derived EBV, cross-reactivity immunostains, amplicon
contamination, or inappropriate technique sensitivity; and
the last issue is the absence of EBV-cancer association hall-
marks including EBERs expression in all cells of virus-associ-
ated tumors. Breast cancer may express EBERs less
abundantly than other malignancies [9–12]. However, EBERs
are not found in all NPCs or in some Burkitt and Hodgkin
lymphomas that are LMP-1 positive by PCR [11–23].
Regarding the association of EBV presence with tumor
grade, there was no statistical signiﬁcant relation between
EBV presence and tumor grade (p> 0.05) in both popula-
tions. The correlation coefﬁcient indicates a weak correlation
where it was 0.114 and 0.269 for Egyptian and Iraqi patients
respectively. This ﬁnding disagrees with that done by Mazouni
et al. [50] where they stated that the proportion of EBV-posi-
tive samples increased signiﬁcantly with increasing tumor
grade, from 16.2% for grade I, to 32.0% and 46.4% for grades
II and III, respectively. The inconsistency in both results might
be due to; (a) the small sample size where our study was done
on 40 Egyptian and 50 Iraqi patients compared to 196 French
breast tumor cases, and (b) the various laboratory methods
that were applied in our study for assessment of EBV genes
and proteins (immunohistochemistry (IHC), in situ hybridiza-
tion (ISH) and PCR), while real time PCR assay has been used
by Mazouni et al. [52] for EBV detection.
In conclusion, our ﬁndings suggest that EBV might have a
role in the pathogenesis of breast cancer. These ﬁndings were
based mainly on EBV detection by PCR technique and con-
ﬁrmed by immunohistochemistry and in situ hybridization
techniques in breast cancer patients from different geographic
region. So, EBV may contribute to increased tumor aggression
even in patients from different geographic region.
Further research is necessary in order to determine the role
of EBV in the etiology or progression of breast cancer, partic-
ularly; it was detected in the lymphocytes around the breast tis-
sues suggesting its contribution as a modulating agent in the
microenvironment area around those breast tissues. In other
words, it may modulate the secretion of interleukin-6 and
tumor necrosis factor which have proven to have a role in
breast cancer development.Acknowledgements
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